Alembic Pharmaceuticals Limited

APLLTD

INE901L01018

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:51 2024-05-31 am EDT			5-day change	1st Jan Change
923.1 ^INR	-2.05%		-2.83%	+21.56%

May. 30	Alembic Pharmaceuticals Gets US FDA Final Nod for Sacubitril and Valsartan Tablets	MT
May. 09	Transcript : Alembic Pharmaceuticals Limited, Q4 2024 Earnings Call, May 09, 2024

Alembic Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24

May 09, 2024 at 04:38 am EDT

Alembic Pharmaceuticals Limited Board meeting held on 9 May, 2024 has recommended dividend on equity shares of INR 11 per equity share 550% for the financial year 2023-24 as against dividend of INR 8 per equity share 400% per equity share for financial year 2022-23.

Latest news about Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Gets US FDA Final Nod for Sacubitril and Valsartan Tablets	May. 30	MT
Transcript : Alembic Pharmaceuticals Limited, Q4 2024 Earnings Call, May 09, 2024	May. 09
Alembic Pharmaceuticals' Consolidated Net Profit Jumps in Fiscal Q4	May. 09	MT
India's Alembic Pharma posts higher Q4 profit on strong N.America sales	May. 09	RE
Alembic Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 09	CI
Alembic Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 09	CI
Alembic Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24	May. 09	CI
Alembic Pharmaceuticals Limited Receives Various US Food & Drug Administration (Tentative or Final) Product Approvals	May. 08	CI
Alembic Pharmaceuticals Limited Receives an Order from the Office of Deputy Commissioner, DGSTO-02, Bengaluru, Karnataka	Apr. 29	CI
Alembic Pharmaceuticals Limited Receives Order from the Office of Deputy Commissioner (ST), Guwahati, Assam	Apr. 26	CI
Alembic Pharmaceuticals Board to Consider Dividend for Fiscal 2024; Shares Drop 3%	Apr. 18	MT
Alembic Pharmaceuticals Limited Received 3 Assessment Orders from the Office of Assistant Commissioner (ST), Andhra Pradesh	Apr. 08	CI
Alembic Pharmaceuticals Appoints Manish Kejriwal as Independent Director	Apr. 02	CI
Alembic Pharmaceuticals Gets US FDA Tentative Nod for Generic Breast Cancer Treatment	Apr. 02	MT
Alembic Pharmaceuticals Limited Receives One US Food & Drug Administration Product Approval	Apr. 01	CI
Alembic Pharmaceuticals Limited Announces Board Cessations	Apr. 01	CI
Alembic Pharmaceuticals Limited Receives Order from Commission of Customs, Mumbai Zone- III	Mar. 18	CI
Alembic Pharmaceuticals' Oncology Plant in Gujarat, India Gets One Observation from US FDA	Mar. 11	MT
Alembic Pharmaceuticals Limited Announces United States Food and Drug Administration Conducted an Inspection At Oncology Formulation Facility At Panelav	Mar. 08	CI
Crisil Keeps AA+ Rating on Alembic Pharmaceuticals' Bank Loans with Stable Outlook	Mar. 08	MT
Indian shares seen muted tracking broader Asian equities	Feb. 25	RE
Alembic Pharmaceuticals Fully Resumes Operations at Manufacturing Unit in South Sikkim, India	Feb. 23	MT
Alembic Pharmaceuticals' Consolidated Net Profit Jumps in Fiscal Q3; EPS Tops Estimates	Feb. 06	MT
Alembic Pharmaceuticals' Consolidated Profit Climbs in Fiscal Q3, EPS Beats Estimates	Feb. 06	MT
Transcript : Alembic Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 05, 2024	Feb. 05

Chart Alembic Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Alembic Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

923.1 INR

Average target price

980.3 INR

Spread / Average Target

+6.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ALEMBIC PHARMACEUTICALS LIMITED	+21.56%	2.22B
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B

Other Pharmaceuticals